AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36114623 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (40 ppm) during DL,NO manoeuvre
Number of subjects: 9
Study 36114623 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalations during DL,NO manoeuvre
Number of subjects: 9
Study 33678639 — intervention group
Group type: EXPERIMENTAL
Intervention: Three high-tension line resection (Group A)
Number of subjects: 0
Study 33678639 — intervention group
Group type: COMPARATOR
Intervention: Two high-tension line resection (Group B)
Number of subjects: 0
Study 33678639 — intervention group
Group type: EXPERIMENTAL
Intervention: Three high-tension line resection (Group C)
Number of subjects: 0
Study 33678639 — intervention group
Group type: COMPARATOR
Intervention: Two high-tension line resection (Group D)
Number of subjects: 0
Study 33678639 — intervention group
Group type: EXPERIMENTAL
Intervention: Three high-tension line resection with anterior deviation (Group E)
Number of subjects: 0
Study 33678639 — intervention group
Group type: COMPARATOR
Intervention: Two high-tension line resection with anterior deviation (Group F)
Number of subjects: 0
Study 33678639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal endoscopy (Group A)
Number of subjects: 0
Study 33678639 — intervention group
Group type: COMPARATOR
Intervention: Nasal endoscopy (Group B)
Number of subjects: 0
Study 33678639 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinomanometry (Group A)
Number of subjects: 0
Study 33678639 — intervention group
Group type: COMPARATOR
Intervention: Rhinomanometry (Group B)
Number of subjects: 0
Study 33142544 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented liquor distiller's grains with solubles (FLDGS)
Number of subjects: 3300
Study 33142544 — intervention group
Group type: COMPARATOR
Intervention: Unfermented liquor distiller's grains with solubles (ULDGS)
Number of subjects: 3300
Study 33142544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ULDGS and FLDGS at various levels (4, 8, 12, 16, and 20%)
Number of subjects: 3300
Study 33142544 — intervention group
Group type: EXPERIMENTAL
Intervention: FLDGS
Number of subjects: 3300
Study 33142544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources and levels of LDGS
Number of subjects: 3300
Study 33559611 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐phycocyanin (C‐PC) with small-molecule additives
Number of subjects: 0
Study 33559611 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐phycocyanin (C‐PC)
Number of subjects: 0
Study 32145474 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX) with pembrolizumab
Number of subjects: 54
Study 36231728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT) for 30 min/day for 4 weeks
Number of subjects: 43
Study 36231728 — intervention group
Group type: COMPARATOR
Intervention: Placebo light
Number of subjects: 43
Study 33691602 — intervention group
Group type: EXPERIMENTAL
Intervention: Online sexual intimacy enhancement training
Number of subjects: 48
Study 33691602 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face sexual intimacy enhancement training
Number of subjects: 48
Study 32639649 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 13
Study 32639649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 32639649 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of Metformin
Number of subjects: 13
Study 35845456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Compensatory Training (CCT)
Number of subjects: 100
Study 35845456 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Interactive Remediation of Cognition—Training for Schizophrenia (CIRCuiTs)
Number of subjects: 100
Study 35845456 — intervention group
Group type: COMPARATOR
Intervention: CCT and CIRCuiTs (both groups)
Number of subjects: 100
Study 32579298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of rosuvastatin/metformin sustained-release (10/1000 mg) in fasted and fed states
Number of subjects: 35
Study 32579298 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of 10 mg rosuvastatin and 1000 mg metformin sustained release in the fed state
Number of subjects: 35
Study 32579298 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of food on pharmacokinetics
Number of subjects: 35
Study 35767271 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate (PCC)
Number of subjects: 100
Study 35767271 — intervention group
Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 100
Study 33971141 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 750 mg orally once daily
Number of subjects: 400
Study 33971141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 36076452 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal diet
Number of subjects: 62
Study 36076452 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 62
Study 33080623 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab monotherapy (20 mg/kg on days 1, 8, 15, and 22 of cycle 1 followed by 20 mg/kg on days 1 and 15 of subsequent cycles)
Number of subjects: 164
Study 33080623 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab combined with dexamethasone (40 mg/d, 20 mg/d for patients aged ≥75 years, once weekly)
Number of subjects: 164
Study 33080623 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but inferred as patients not receiving dexamethasone)
Number of subjects: 164
Study 36265267 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal O2 (SpO2 > 96%)
Number of subjects: 20
Study 36265267 — intervention group
Group type: COMPARATOR
Intervention: Conservative O2 (SpO2: 90–94%)
Number of subjects: 20
Study 36265267 — intervention group
Group type: COMPARATOR
Intervention: Conservative O2
Number of subjects: 20
Study 36265267 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal O2
Number of subjects: 20
Study 33883254 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL-PF/ADL-PF
Number of subjects: 552
Study 33883254 — intervention group
Group type: COMPARATOR
Intervention: ADL-EU/ADL-EU
Number of subjects: 552
Study 33883254 — intervention group
Group type: COMPARATOR
Intervention: ADL-EU/ADL-PF
Number of subjects: 552
Study 32078471 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise (WBVE) group (n = 17); 10 sessions (2 times/week), 18 min/session, frequency from 5 to 14 Hz, peak-to-peak displacement of 2.5, 5.0, and 7.5 mm
Number of subjects: 33
Study 32078471 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16); same protocol as WBVE but with the vibrating platform turned off
Number of subjects: 33
Study 36256584 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow maxillary expansion (SME) activated once every other day
Number of subjects: 30
Study 36256584 — intervention group
Group type: COMPARATOR
Intervention: Rapid maxillary expansion (RME) activated twice daily
Number of subjects: 30
Study 33418095 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta frequency bilateral STN stimulation (10 Hz)
Number of subjects: 12
Study 33418095 — intervention group
Group type: COMPARATOR
Intervention: Gamma frequency bilateral STN stimulation (130–135 Hz)
Number of subjects: 12
Study 33418095 — intervention group
Group type: COMPARATOR
Intervention: Off stimulation
Number of subjects: 12
Study 32683790 — intervention group
Group type: EXPERIMENTAL
Intervention: l-citrulline (3 g) daily for 2 months
Number of subjects: 54
Study 32683790 — intervention group
Group type: COMPARATOR
Intervention: microcrystalline cellulose (placebo) daily for 2 months
Number of subjects: 54
Study 32779919 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prednisolone per day for 6 weeks
Number of subjects: 0
Study 32779919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34793405 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (endogenous opioid antagonist)
Number of subjects: 27
Study 34793405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 33808080 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative deprescribing intervention by a pharmacist and a physician
Number of subjects: 72
Study 33808080 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 72
Study 33808080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 72
Study 33808080 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 32274521 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based stabilization exercises focusing on pelvic floor muscles (PFM) 3 days a week for 12 weeks, three sets a day; each set included three different types of exercise each week
Number of subjects: 80
Study 32274521 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 80
Study 35962772 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 143
Study 35962772 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC)
Number of subjects: 143
Study 33967047 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF6019
Number of subjects: 26
Study 33967047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 33967047 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF6019 and Placebo
Number of subjects: 26
Study 32616263 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/kg VC
Number of subjects: 180
Study 32616263 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg/kg VC
Number of subjects: 180
Study 32616263 — intervention group
Group type: COMPARATOR
Intervention: SE challenge
Number of subjects: 180
Study 32616263 — intervention group
Group type: EXPERIMENTAL
Intervention: VC supplementation
Number of subjects: 180
Study 35218725 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus individualized, point-of-purchase nutrition education
Number of subjects: 267
Study 35218725 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus individualized, point-of-purchase nutrition education enhanced with online shopping technologies and training
Number of subjects: 267
Study 35218725 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 267
Study 33451596 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine patches
Number of subjects: 61
Study 33451596 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches (hydrocolloid)
Number of subjects: 61
Study 33518471 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical xylometazoline (0.1%)
Number of subjects: 148
Study 33518471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline nasal spray, 0.74% w/v isotonic solution)
Number of subjects: 148
Study 34644350 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM Wheels training program (peer-led teleconference training sessions and video-based training application)
Number of subjects: 0
Study 34644350 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list control)
Number of subjects: 0
Study 35346603 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 586
Study 35346603 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid + ezetimibe fixed-dose combination
Number of subjects: 586
Study 35346603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 32043706 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl
Number of subjects: 0
Study 32043706 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 0
Study 32043706 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl/EDTA
Number of subjects: 0
Study 32043706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 pH 12.6
Number of subjects: 0
Study 32043706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 pH 9.8
Number of subjects: 0
Study 32043706 — intervention group
Group type: COMPARATOR
Intervention: Formal-saline control-1
Number of subjects: 0
Study 32043706 — intervention group
Group type: COMPARATOR
Intervention: Formal-saline control-2
Number of subjects: 0
Study 36112645 — intervention group
Group type: EXPERIMENTAL
Intervention: US-detected group (n = 1,062)
Number of subjects: 1289
Study 36112645 — intervention group
Group type: COMPARATOR
Intervention: US-missed group (n = 227)
Number of subjects: 1289
Study 36112645 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind spots (HCC ≥ 2 cm)
Number of subjects: 1289
Study 36112645 — intervention group
Group type: EXPERIMENTAL
Intervention: US-detected group (blind spot HCC)
Number of subjects: 1289
Study 36112645 — intervention group
Group type: COMPARATOR
Intervention: Non-blind area HCC
Number of subjects: 1289
Study 32379667 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) for 30 min per day for 5 consecutive days
Number of subjects: 51
Study 32379667 — intervention group
Group type: COMPARATOR
Intervention: Routine care and treatment (Control)
Number of subjects: 51
Study 34525122 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor D (selenium/alpha‐tocopherol/beta‐carotene)
Number of subjects: 29553
Study 34525122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 29553
Study 34880010 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL convalescent plasma (CP) daily for up to 10 days (until virus negative in blood) plus standard care
Number of subjects: 900
Study 34880010 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 900
Study 32871264 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth shoulder examination (STE)
Number of subjects: 62
Study 32871264 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical examination (SCE)
Number of subjects: 62
Study 35688014 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction risk information
Number of subjects: 1546
Study 35688014 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction plus health risk information
Number of subjects: 1546
Study 35688014 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction plus death risk information
Number of subjects: 1546
Study 35688014 — intervention group
Group type: COMPARATOR
Intervention: No additional information (control)
Number of subjects: 1546
Study 33573735 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure using Amplatzer PFO Occluder
Number of subjects: 337
Study 33573735 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 337
Study 32651582 — intervention group
Group type: EXPERIMENTAL
Intervention: Three referees
Number of subjects: 98
Study 32651582 — intervention group
Group type: COMPARATOR
Intervention: One referee
Number of subjects: 98
Study 35103547 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-Rich Platelet-Rich Plasma (LR-PRP)
Number of subjects: 192
Study 35103547 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte-Poor Platelet-Rich Plasma (LP-PRP)
Number of subjects: 192
Study 33128303 — intervention group
Group type: COMPARATOR
Intervention: Aspartame (ASP) at a dose of 40 mg/kg/day
Number of subjects: 4
Study 33128303 — intervention group
Group type: COMPARATOR
Intervention: Caffeine at a dose of 80 mg/kg/day
Number of subjects: 4
Study 33128303 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (ASP) and caffeine combined at previous doses
Number of subjects: 4
Study 32486910 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial pleasantness quantitative sensory testing
Number of subjects: 16
Study 32486910 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial unpleasantness quantitative sensory testing
Number of subjects: 16
Study 34896605 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 44
Study 34896605 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training (TT)
Number of subjects: 44
Study 34563924 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (FPV)
Number of subjects: 780
Study 34563924 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy only
Number of subjects: 780
Study 34015659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenate (12.5 μg Se kg−1 soil)
Number of subjects: 29
Study 34015659 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of Se)
Number of subjects: 29
Study 33118519 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical ozone oil (1 mL, applied locally 3 times per day for 12 weeks)
Number of subjects: 91
Study 33118519 — intervention group
Group type: COMPARATOR
Intervention: Urea ointment (10% urea, 2 g, applied locally 3 times per day for 12 weeks)
Number of subjects: 91
Study 33118519 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical ozone oil
Number of subjects: 91
Study 33118519 — intervention group
Group type: COMPARATOR
Intervention: Urea ointment
Number of subjects: 91
Study 34011342 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative LMWH administration (4000 IU per day)
Number of subjects: 246
Study 34011342 — intervention group
Group type: COMPARATOR
Intervention: Postoperative LMWH administration (4000 IU per day)
Number of subjects: 246
Study 32147037 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) plus exercise
Number of subjects: 40
Study 32147037 — intervention group
Group type: COMPARATOR
Intervention: Combination of Ultrasound (US), Transcutaneous Nerve Stimulation (TENS) and exercise
Number of subjects: 40
Study 35801815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-focus contact lenses with 2.1 mm inner zone diameter (S design)
Number of subjects: 28
Study 35801815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-focus contact lenses with 4.0 mm inner zone diameter (M design)
Number of subjects: 28
Study 35801815 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dual-focus contact lenses
Number of subjects: 28
Study 33706570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful walking practice (usual care plus mindful walking)
Number of subjects: 78
Study 33706570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful walking practice
Number of subjects: 78
Study 33706570 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 78
Study 32429848 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-based recruitment strategy
Number of subjects: 13251
Study 32429848 — intervention group
Group type: COMPARATOR
Intervention: Email-based recruitment strategy
Number of subjects: 13251
Study 35175070 — intervention group
Group type: EXPERIMENTAL
Intervention: iSOMA intervention (8-week guided cognitive-behavioral internet intervention with psychologist support)
Number of subjects: 158
Study 35175070 — intervention group
Group type: EXPERIMENTAL
Intervention: iSOMA intervention
Number of subjects: 158
Study 35175070 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 158
Study 33947886 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) classifier
Number of subjects: 229
Study 33947886 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature-selected RF with serum potassium, plasma aldosterone, and serum sodium levels
Number of subjects: 229
Study 33947886 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature-selected RF with an independent external PA cohort
Number of subjects: 229
Study 33015809 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administration (MED)
Number of subjects: 3
Study 33015809 — intervention group
Group type: COMPARATOR
Intervention: Model group (MOD)
Number of subjects: 3
Study 33453066 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (inguinal region)
Number of subjects: 6
Study 33453066 — intervention group
Group type: EXPERIMENTAL
Intervention: TXM (metacarpus)
Number of subjects: 6
Study 33453066 — intervention group
Group type: EXPERIMENTAL
Intervention: TXT (ventral tail base)
Number of subjects: 6
Study 33453066 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 6
Study 33872284 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green fluoroscopy
Number of subjects: 347
Study 33872284 — intervention group
Group type: COMPARATOR
Intervention: Standard evaluation of tissue perfusion
Number of subjects: 347
Study 36143973 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 0
Study 36143973 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial Plexus Block (BPB)
Number of subjects: 0
Study 33781915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pabinafusp alfa at 1.0 mg/kg/week
Number of subjects: 3
Study 33781915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pabinafusp alfa at 2.0 mg/kg/week
Number of subjects: 3
Study 33781915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pabinafusp alfa at 4.0 mg/kg/week
Number of subjects: 3
Study 33781915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pabinafusp alfa (all dosages)
Number of subjects: 3
Study 35660738 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster doses of CoronaVac
Number of subjects: 2
Study 35606757 — intervention group
Group type: EXPERIMENTAL
Intervention: Online ESRD communication skills training (CST)
Number of subjects: 91
Study 35606757 — intervention group
Group type: COMPARATOR
Intervention: Regular in-service training (Control Group)
Number of subjects: 91
Study 33085106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled room
Number of subjects: 60
Study 33085106 — intervention group
Group type: COMPARATOR
Intervention: Warmed room
Number of subjects: 60
Study 33085106 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification with the suffering protagonist
Number of subjects: 60
Study 33085106 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-social relationship with the protagonist
Number of subjects: 60
Study 33343577 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccines (QIVs)
Number of subjects: 16
Study 35361657 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pill containing quadruple combination of quarter doses of blood pressure medicines
Number of subjects: 0
Study 35361657 — intervention group
Group type: COMPARATOR
Intervention: Standard dose irbesartan
Number of subjects: 0
Study 33124749 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake of 180 mg shortly before surgery (intervention group)
Number of subjects: 2
Study 33124749 — intervention group
Group type: COMPARATOR
Intervention: No caffeine (control group)
Number of subjects: 2